Matrix Metalloproteinases and the Plasminogen System in Tumor Progression

  • Yves A. DeClerck
  • Walter E. Laug

Abstract

Extracellular proteases play an important contributory role in cancer progression. Proteases are expressed by tumor and stromal cells in the tumor microenvironment, where they proteolytically modify a large variety of extracellular proteins. The mechanisms by which they contribute to tumor progression are multiple and becoming increasingly complex. By degrading proteins that constitute the extracellular matrix (ECM), proteases promote the invasion of tumor cells into surrounding tissues and blood vessels and contribute to the development of distant metastases. They also play a positive role in angiogenesis by promoting the penetration of malignant tissues by endothelial cells. The proteolytic spectrum of these proteases is, however, not restricted to ECM proteins as many proteins that control critical cellular functions such as cell adhesion, growth and survival, like growth factors, cell surface receptors and growth factor binding proteins, are also the target of these proteases. Among the multiple proteases that play a key role in cancer progression are the matrix metalloproteinases (MMPs) and the plasminogen activator-plasmin (PA) system referred here as the plasminogen system. The contribution of these proteases to cancer has been the subject of an abundant scientific literature. However, these two families of proteases have often been studied independently of each other and it is uncertain whether their function in cancer overlaps in a redundant or complementary manner. In this article, interactive aspects between MMPs and the plasminogen system will be discussed first at a biochemical level. How these interactions could play a role in cancer biology will then be reviewed. Because the biochemistry of the plasminogen system is discussed in detail in other chapters, it will not be reviewed here.

Keywords

Manes Integrin Gelatin Fibrinogen Neuroblastoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adachi, Y., Yamamoto, H., Itoh, F., Hinoda, Y., Okada, Y., and Imai, K. (1999). Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 45, 252–258.PubMedCrossRefGoogle Scholar
  2. Anand-Apte, B., Pepper, M.S., Voest, E., Montesano, R., Olsen, B., Murphy, G., Apte, S.S., and Zetter, B. (1997). Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest. Ophthalmol. Vis. Sci. 38, 817–823.PubMedGoogle Scholar
  3. Bajou, K., Masson, V., Gerard, R.D., Schmitt, P.M., Albert, V., Praus, M., Lund, L.R., Frandsen, T.L., Brunner, N., Dano, K., Fusenig, N.E., Weidle, U., Carmeliet, G., Loskutoff, D., Collen, D., Carmeliet, P., Foidart, J.M., and Noel, A. (2001). The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J. Cell. Biol. 152, 777–784.PubMedCrossRefGoogle Scholar
  4. Bajou, K., Noel, A., Gerard, R.D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N.E., Carmeliet, P., Collen, D., and Foidart, J.M. (1998). Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4, 923–928.PubMedCrossRefGoogle Scholar
  5. Basset, P., Wolf, C., and Chambon, P. (1993). Expression of the stromelysin-3 gene in fìbroblastic cells of invasive carcinomas of the breast and other human tissues: A review. Breast Cancer Res. Treat. 24, 185–193.PubMedCrossRefGoogle Scholar
  6. Bini, A., Wu, D., Schnuer, J., and Kudryk, B.J. (1999). Characterization of stromelysin 1 (MMP-3), matrilysin (MMP-7), and membrane type 1 matrix metalloproteinase (MT1-MMP) derived fibrin(ogen) fragments D-dimer and D-like monomer: NH2-terminal sequences of late- stage digest fragments. Biochemistry 38, 13928–13936.PubMedCrossRefGoogle Scholar
  7. Bugge, T.H., Kombrinck, K.W., Xiao, Q., Holmbäck, K., Daugherty, C.C., Witte, D.P., and Degen, J.L. (1997). Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood 90, 4522–4531.PubMedGoogle Scholar
  8. Chang, C. and Werb, Z. (2001). The many faces of metalloproteases: Cell growth, invasion, angiogenesis and metastasis. Trends Cell. Biol. 11, S37–S43.PubMedGoogle Scholar
  9. Coussens, L.M., Fingleton, B., and Matrisian, L.M. (2002). Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295, 2387–2392.PubMedCrossRefGoogle Scholar
  10. Coussens, L.M., Tinkle, C.L., Hanahan, D., and Werb, Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481–490.PubMedCrossRefGoogle Scholar
  11. Crawford, H.C., Fingleton, B.M., Rudolph-Owen, L.A., Goss, K.J.H., Rubinfeld, B., Polakis, P., and Matrisian, L.M. (1999). The metalloproteinase matrilysin is a target of b-catenin transactivation in intestinal tumors. Oncogene 18, 2883–2891.PubMedCrossRefGoogle Scholar
  12. Crawford, H.C., Scoggins, C.R., Washington, M.K., Matrisian, L.M., and Leach, S.D. (2002). Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J. Clin. Invest. 109, 1437–1444.PubMedGoogle Scholar
  13. DeClerck, Y.A., Imren, S., Montgomery, A.M P., Mueller, B.M., Reisfeld, R.A., and Laug, W.E. (1997). Proteases and protease inhibitors in tumor progression. Adv. Exp. Med. Biol. 425, 89–97.PubMedCrossRefGoogle Scholar
  14. Dong, Z., Kumar, R., Yang, X., and Fidler, I.J. (1997). Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88, 801–810.PubMedCrossRefGoogle Scholar
  15. Duffy, M.J. (1996). Proteases as prognostic markers in cancer. Clin. Cancer Res. 2, 613–618.PubMedGoogle Scholar
  16. Emonds-Alt, X., Quisquater, E., and Vaes, G. (1980). Proteoglycan- and fibrin-degrading neutral proteinase activities of Lewis lung carcinoma cells. Eur. J. Cancer 16, 1257–1261.PubMedCrossRefGoogle Scholar
  17. Freije, J.M., Diez Itza, I., Balbin, M., Sanchez, L.M., Blasco, R., Tolivia, J., and Lopez Otin, C. (1994). Molecular cloning and expression of collagenase-3,a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem. 269, 16766–16773.PubMedGoogle Scholar
  18. Ginestra, A., Monea, S., Seghezzi, G., Dolo, V., Nagase, H., Mignatti, P., and Vittorelli, M.L. (1997). Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J. Biol. Chem. 272, 17216–17222.PubMedCrossRefGoogle Scholar
  19. Grant, G.M., Giambernardi, T.A., Grant, A.M., and Klebe, R.J. (1999). Overview of expression of matrix metalloproteinases (MMP-17, MMP- 18, and MMP-20) in cultured human cells. Matrix Biol. 18, 145–148.PubMedCrossRefGoogle Scholar
  20. Gray, ST., Wilkins, R.J., and Yun, K. (1992). Interstitial collagenase gene expression in oral squamous cell carcinoma. Am. J. Pathol. 141, 301–306.PubMedGoogle Scholar
  21. Gray, ST., Yun, K., Motoori, T., and Kuys, Y.M. (1993). Interstitial collagenase gene expression in colonic neoplasia. Am. J. Pathol. 143, 663–671.PubMedGoogle Scholar
  22. Guo, H.M., Majmudar, G., Jensen, T.C., Biswas, C, Toole, B.P., and Gordon, M.K. (1998). Characterization of the gene for human EMMPRIN, a tumor cell surface inducer of matrix metalloproteinases. Gene 220,99–108.PubMedCrossRefGoogle Scholar
  23. Hahn-Dantona, E., Ramos-DeSimone, N., Sipley, J., Nagase, H., French, D.L., and Quigley, J.P. (1999).Activation of ProMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases. Ann. NY Acad. Sci. 878, 372–387.PubMedCrossRefGoogle Scholar
  24. Hajjar, K.A. and Deora, A. (2000). New concepts in fibrinolysis and angiogenesis. Curr Atheroscler. Rep. 2,417–421.PubMedCrossRefGoogle Scholar
  25. Hiller, O., Lichte, A., Oberpichler, A., Kocourek, A., and Tschesche, H. (2000). Matrix metalloproteinases collagenase-2, macrophage elastase, collagenase-3, and membrane type 1-matrix metalloproteinase impair clotting by degradation of fibrinogen and factor XII. J. Biol. Chem. 275, 33008–33013.PubMedCrossRefGoogle Scholar
  26. Hiraoka, N., Allen, E., Apel, I.J., Gyetko, M.R., and Weiss, S.J. (1998). Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95, 365–377.PubMedCrossRefGoogle Scholar
  27. Holmbeck, K., Bianco, P., Caterina, J., Yamada, S., Kromer, M., Kuznetsov, S.A., Mankani, M., Robey, P.G.,Poole, A.R., Pidoux, I., Ward, J.M., and Birkedal-Hansen, H. (1999). MTl-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99,81–92.PubMedCrossRefGoogle Scholar
  28. Isogai, C., Laug, W.E., Shimada, H., Declerck, P.J., Stins, M.F., Durden, D.L., Erdreich-Epstein, A., and DeClerck, Y.A. (2001). Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res. 61, 5587–5594.PubMedGoogle Scholar
  29. Jilek, F. and Hormann, H. (1977). Cold-insoluble globulin, II[1,2]. Cyanogen bromide and plasminolysis fragments containing a label introduced by transamidation. Hoppe Seylers. Z. Physiol. Chem. 358, 1165–1168.PubMedGoogle Scholar
  30. Kajita, M., Itoh, Y., Chiba, T., Mori, H., Okada, A., Kinoh, H., and Seiki, M. (2001). Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell. Biol. 153, 893–904.PubMedCrossRefGoogle Scholar
  31. Knauper, V., Will, H., Lopez-Otin, C., Smith, B., Atkinson, S.J., Stanton, H., Hembry, R.M., and Murphy, G.(1996). Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J. Biol. Chem. 271, 17124–17131.PubMedCrossRefGoogle Scholar
  32. Koblinski, J.E., Ahram, M., and Sloane, B.F. (2000). Unraveling the role of proteases in cancer. Clin. Chim. Acta 291, 113–135.PubMedCrossRefGoogle Scholar
  33. Koolwijk, P., Sidenius, N., Peters, E., Sier, C.F., Hanemaaijer, R., Blasi, F., and van Hinsbergh, V.W. (2001).Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: Implication for angiogenesis in fibrin matrices. Blood 97, 3123–3131.PubMedCrossRefGoogle Scholar
  34. Levi, M., Moons, L., Bouche, A., Shapiro, S.D., Collen, D., and Carmeliet, P. (2001). Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice. Circulation 103, 2014–2020.PubMedCrossRefGoogle Scholar
  35. Lijnen, H.R. (2002). Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc.) 67, 92–98.CrossRefGoogle Scholar
  36. Lijnen, H.R., Arza, B., Van Hoef, B., Collen, D., and Declerck, P.J. (2000). Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3). J. Biol. Chem. 275, 37645–37650.PubMedCrossRefGoogle Scholar
  37. Lijnen, H.R., Silence, J., Lemmens, G., Frederix, L., and Collen, D. (1998a). Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system. Thromb. Haemost. 79,1171–1176.PubMedGoogle Scholar
  38. Lijnen, H.R., Ugwu, F., Bini, A., and Collen, D. (1998b). Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 37, 4699–4702.PubMedCrossRefGoogle Scholar
  39. Lund, L.R., Romer, J., Bugge, T.H., Nielsen, B.S., Frandsen, T.L., Degen, J.L., Stephens, R.W., and Dano, K.(1999). Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J.18, 4645–4656.PubMedCrossRefGoogle Scholar
  40. Mackay, A.R., Corbitt, R.H., Hartzler, J.L., and Thorgeirsson, U.P. (1990). Basement membrane type IV collagen degradation: Evidence for the involvement of a proteolytic cascade independent of metalloproteinases.Cancer Res. 50, 5997–6001.PubMedGoogle Scholar
  41. Manes, S., Llorente, M., Lacalle, R.A., Gomez-Mouton, C., Kremer, L., Mira, E., and Martinez, A. (1999).The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J. Biol. Chem. 274, 6935–6945.PubMedCrossRefGoogle Scholar
  42. Marchenko, G.N., Ratnikov, B.I., Rozanov, D.V., Godzik, A., Deryugina, E.I., and Strongin, A.Y. (2001).Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem. J. 356, 705–718.PubMedCrossRefGoogle Scholar
  43. Matrisian, L.M. and Bowden, G.T. (1990). Stromelysin/transin and tumor progression. Semin. Cancer Biol. 1, 107–115.PubMedGoogle Scholar
  44. Mazzieri, R., Masiero, L., Zanetta, L., Monea, S., Onisto, M., Garbisa, S., and Mignatti, P. (1997). Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants. EMBO J. 16, 2319–2332.PubMedCrossRefGoogle Scholar
  45. McCawley, L.J. and Matrisian, L.M. (2001). Matrix Metalloproteinases: They’re not just for matrix anymore. Curr. Opin. Cell. Biol. 13, 534–540.PubMedCrossRefGoogle Scholar
  46. McDonnell, S., Navre, M., Coffey, R., Jr., and Matrisian, L.M. (1991). Expression and localization of the matrix metalloproteinase pump- 1 (MMP-7) in human gastric and colon carcinomas. Mol. Carcinog. 4, 527–533.PubMedCrossRefGoogle Scholar
  47. Mignatti, P. and Rifkin, D.B. (1996). Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49, 117–137.PubMedGoogle Scholar
  48. Montgomery, A.M., DeClerck, Y.A., Langley, K.E., Reisfeld, R.A., and Mueller, B.M. (1993). Melanoma-mediated dissolution of extracellular matrix: Contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res. 53, 693–700.PubMedGoogle Scholar
  49. Montgomery, A.M., Mueller, B.M., Reisfeld, R.A., Taylor, S.M., and DeClerck, Y.A. (1994). Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res. 54, 5467–5473.PubMedGoogle Scholar
  50. Mueller, B.M. (1996). Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr. Top. Microbiol. Immunol. 213, 65–80.PubMedCrossRefGoogle Scholar
  51. Mueller, B.M., Yu, Y.B., and Laug, W.E. (1995). Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid mice. Proc. Natl. Acad. Sci. USA 92, 205–209.PubMedCrossRefGoogle Scholar
  52. Murphy, G., Ward, R., Gavrilovic, J., and Atkinson, S. (1992). Physiological mechanisms for metalloproteinase activation. Matrix Suppl. 1, 224–230.PubMedGoogle Scholar
  53. Nagase, H. (1997). Activation mechanisms of matrix metalloproteinases. Biol. Chem. Hoppe Seyler 378, 151–160.Google Scholar
  54. Nagase, H. and Woessner, J.F., Jr. (1999). Matrix metalloproteinases. J. Biol. Chem. 274, 21491–21494.PubMedCrossRefGoogle Scholar
  55. Nelson, A.R., Fingleton, B., Rothenberg, M.L., and Matrisian, L.M. (2000). Matrix metalloproteinases: Biologic activity and clinical implications. J. Clin. Oncol. 18, 1135–1149.PubMedGoogle Scholar
  56. Nielsen, B.S., Timshel, S., Kjeldsen, L., Sehested, M., Pyke, C., Borregaard, N., and Dano, K. (1996). 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int. J. Cancer. 65, 57–62.PubMedCrossRefGoogle Scholar
  57. Noel, A., Lefebvre, O., Maquoi, E., VanHoorde, L., Chenard, M.P., Mareel, M., and Foidart, J.M. (1996). Stromelysin-3 expression promotes tumor take in nude mice. J. Clin. Invest. 97, 1924–1930.PubMedCrossRefGoogle Scholar
  58. O’Reilly, M.S., Wiederschain, D., Stetler-Stevenson, W.G., Folkman, J., and Moses, M.A. (1999). Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J. Biol. Chem. 274,29568–29571.CrossRefGoogle Scholar
  59. Okada, Y., Morodomi, T., Enghild, J.J., Suzuki, K., Yasui, A., Nakanishi, I., Salvesen, G., and Nagase, H. (1990). Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur. J. Biochem. 194, 721–730.PubMedCrossRefGoogle Scholar
  60. Patterson, B.C. and Sang, Q.A. (1997). Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J. Biol. Chem. 272, 28823–28825.PubMedCrossRefGoogle Scholar
  61. Pepper, M.S. (1997). Manipulating angiogenesis-from basic science to the bedside. Arterioscler. Thromb. Vasc. Biol. 17, 605–619.PubMedCrossRefGoogle Scholar
  62. Pepper, M.S. (2001). Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol 21, 1104–1117.PubMedCrossRefGoogle Scholar
  63. Poulsom, R., Pignatelli, M., Stetler-Stevenson, W.G., Liotta, L.A., Wright, P.A., Jeffery, R.E., Longcroft, J.M., Rogers, L., and Stamp, G.W. (1992). Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am. J. Pathol. 141, 389–396.PubMedGoogle Scholar
  64. Powell, W.C., Fingleton, B., Wilson, C.L., Boothby, M., and Matrisian, L.M. (1999). The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. 9, 1441–1447.PubMedCrossRefGoogle Scholar
  65. Powell, W.C. and Matrisian, L.M. (1996). Complex roles of matrix metalloproteinases in tumor progression. Curr. Top. Microbiol. Immunol. 213, 1–21.PubMedCrossRefGoogle Scholar
  66. Pozzi, A., LeVine, W.F., and Gardner, H.A. (2002). Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 21, 272–281.PubMedCrossRefGoogle Scholar
  67. Pozzi, A., Moberg, P.E., Miles, L.A., Wagner, S., Soloway, P., and Gardner, H.A. (2000). Elevated matrix metallo-protease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc. Natl. Acad. Sci. USA 97, 2202–2207.PubMedCrossRefGoogle Scholar
  68. Rao, J.S., Steck, P.A., Mohanam, S., Stetler-Stevenson, W.G., Liotta, L.A., and Sawaya, R. (1993). Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res. 53, 2208–2211.PubMedGoogle Scholar
  69. Rosenthal, E.L., Johnson, T.M., Allen, E.D., Apel, I.J., Punturieri, A., and Weiss, S.J. (1998). Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res. 58, 5221–5230.PubMedGoogle Scholar
  70. Santala, A., Saarinen, J., Kovanen, P., and Kuusela, P. (1999). Activation of interstitial collagenase, MMP-1, by Staphylococcus aureus cells having surface-bound plasmin: A novel role of plasminogen receptors of bacteria. FEBS Lett. 461, 153–156.PubMedCrossRefGoogle Scholar
  71. Sawaya, R.E., Yamamoto, M., Gokaslan, Z.L., Wang, S.W., Mohanam, S., Fuller, G.N., McCutcheon, I.E., Stetler-Stevenson, W.G., Nicolson, G.L., and Rao, J.S. (1996). Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin. Exp. Metastasis 14, 35–42.PubMedCrossRefGoogle Scholar
  72. Schlechte, W., Murano, G., and Boyd, D. (1989). Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res. 49, 6064–6069.PubMedGoogle Scholar
  73. Seiki, M. (1996). Membrane type matrix metalloproteinase and tumor invasion. Curr. Top. Microbiol. Immunol. 213, 23–32.PubMedCrossRefGoogle Scholar
  74. Shofuda, K., Moriyama, K., Nishihashi, A., Higashi, S., Mizushima, H., Yasumitsu, H., Miki, K., Sato, H., Seiki, M., and Miyazaki, K. (1998). Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membrane- type matrix metalloproteinase-1 (MT1-MRP) in human cancer cells. J. Biochem. (Tokyo) 124, 462–470.CrossRefGoogle Scholar
  75. Sounni, N.E., Baramova, E.N., Munaut, C., Maquoi, E., Frankenne, F., Foidart, J.M., and Noel, A. (2002). Expression of membrane type 1 matrix metalloproteinase (MT1-MMP) in A2058 melanoma cells is associated with MMP-2 activation and increased tumor growth and vascularization. Int. J. Cancer 98, 23–28.PubMedCrossRefGoogle Scholar
  76. Sternlicht, M.D., Lochter, A., Sympson, C.J., Huey, B., Rougier, J.P., Gray, J.W., Pinkel, D., Bissell, M.J., and Werb, Z. (1999). The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 98, 137–146.PubMedCrossRefGoogle Scholar
  77. Stetler-Stevenson, W.G. (1990). Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 9, 289–303.PubMedCrossRefGoogle Scholar
  78. Stetler Stevenson, W.G., Liotta, L.A., and Brown, P.D. (1992). Role of type IV collagenases in human breast cancer. Cancer Treat. Res. 61, 21–41.PubMedCrossRefGoogle Scholar
  79. Sugiura, Y., Ma, L.Q., Sun, B., Shimada, H., Laug, W.E., Seeger, R.C., and DeClerck, Y.A. (1999). The plasminogen-plasminogen activator (PA) system in neuroblastoma: Role of PA inhibitor-1 in metastasis. Cancer Res. 59, 1327–1336.PubMedGoogle Scholar
  80. Sugiura, Y., Shimada, H., Seeger, R.C., Laug, W.E., and DeClerck, Y.A. (1998). Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: Contribution of stromal cells to their production and correlation with metastasis. Cancer Res. 58, 2209–2216.PubMedGoogle Scholar
  81. Takigawa, M., Nishida, Y., Suzuki, F., Kishi, J., Yamashita, K., and Hayakawa, T. (1990). Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). Biochem. Biophys. Res. Commun. 171, 1264–1271.PubMedCrossRefGoogle Scholar
  82. Tanimoto, H., Underwood, L.J., Shigemasa, K., Parmley, T.H., Wang, Y.X., Yan, Y., Clarke, J., and O’Brien, T.J. (1999). The matrix metalloprotease pump-1 (MMP-7, matrilysin): A candidate marker/target for ovarian cancer detection and treatment. Tumor Biol. 20, 88–98.CrossRefGoogle Scholar
  83. Uria, J.A., Stahle-Backdahl, M., Seiki, M., Fueyo, A., and Lopez-Otin, C. (1997). Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res. 57, 4882–4888.PubMedGoogle Scholar
  84. Vassalli, J.D. and Pepper, M.S. (1994). Tumour biology. Membrane proteases in focus. Nature 370, 14–15.PubMedCrossRefGoogle Scholar
  85. Väisänen, A., Kallioinen, M., Taskinen, P.J., and Turpeenniemi-Hujanen, T. (1998). Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J. Pathol. 186, 51–58.PubMedCrossRefGoogle Scholar
  86. Vu, T.H., Shipley, J.M., Bergers, G., Berger, J.E., Helms, J.A., Hanahan, D., Shapiro, S.D., Senior, R.M., and Werb, Z. (1998). MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93, 411–422.PubMedCrossRefGoogle Scholar
  87. Whitelock, J.M., Murdoch, A.D., Iozzo, R.V., and Underwood, PA. (1996). The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 271, 10079–10086.PubMedCrossRefGoogle Scholar
  88. Wilson, C.L., Heppner, K.J., Labosky, P.A., Hogan, B.L.M., and Matrisian, L.M. (1997). Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA 94, 1402–1407.PubMedCrossRefGoogle Scholar
  89. Wilson, C.L., Ouellette, A.J., Satchell, D.P., Ayabe, T., López-Boado, Y.S., Stratman, J.L., Hultgren, S.J.,Matrisian, L.M., and Parks, W.C. (1999). Regulation of intestinal a-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 286, 113–117.PubMedCrossRefGoogle Scholar
  90. Windsor, L.J., Grenett, H., Birkedal-Hansen, B., Bodden, M.K., Engler, J.A., and Birkedal-Hansen, H. (1993).Cell type-specific regulation of SL-1 and SL-2 genes. Induction of the SL-2 gene but not the SL-1 gene by human keratinocytes in response to cytokines and phorbolesters. J. Biol. Chem. 268, 17341–17347.PubMedGoogle Scholar
  91. Zucker, S., Cao, J., and Chen, W.T. (2000). Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642–6650.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Yves A. DeClerck
    • 1
    • 2
  • Walter E. Laug
    • 1
    • 2
  1. 1.Division of Hematology-Oncology and Departments of Pediatrics and Biochemistry and Molecular BiologyChildrens Hospital Los AngelesLos AngelesUSA
  2. 2.USC Keck School of MedicineLos AngelesUSA

Personalised recommendations